Sep 8, 2009 - Protalix BioTherapeutics, Inc., announced today that it has received notice from the U.S. FDA that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
The details can be read here.
No comments:
Post a Comment